Free tool
FAERS Monitor: Monoket
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020215 or its brand name (Monoket, Isosorbide Mononitrate). Reports on generic versions are filed under their own applications.
Reports
20,958
Serious
17,559
84% of reports
Hospitalization
9,945
Death reported
2,621
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,592
- dizziness1,487
- diarrhoea1,331
- fatigue1,328
- nausea1,301
- chest pain1,239
- headache1,095
- myocardial infarction1,074
- vomiting998
- hypotension960
- off label use951
- malaise947
- acute kidney injury921
- pain908
- fall862
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 456 |
| 2005 | 540 |
| 2006 | 517 |
| 2007 | 396 |
| 2008 | 616 |
| 2009 | 518 |
| 2010 | 455 |
| 2011 | 661 |
| 2012 | 820 |
| 2013 | 533 |
| 2014 | 858 |
| 2015 | 1,022 |
| 2016 | 1,162 |
| 2017 | 1,198 |
| 2018 | 1,477 |
| 2019 | 1,416 |
| 2020 | 1,179 |
| 2021 | 973 |
| 2022 | 1,266 |
| 2023 | 1,527 |
| 2024 | 1,154 |
| 2025 | 1,256 |
| 2026 | 953 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,201 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chest painSignal | 1,239 | 6.8 | 6.4 | 6,078 |
| myocardial infarctionSignal | 1,074 | 6.2 | 5.9 | 4,699 |
| acute kidney injurySignal | 921 | 6.1 | 5.7 | 3,900 |
| hypotensionSignal | 960 | 4.8 | 4.5 | 2,918 |
| dizzinessSignal | 1,487 | 3.0 | 2.9 | 2,020 |
| dyspnoeaSignal | 1,592 | 2.8 | 2.7 | 1,925 |
| fallSignal | 862 | 2.6 | 2.4 | 861 |
| malaiseSignal | 947 | 2.2 | 2.0 | 607 |
| vomitingSignal | 998 | 2.1 | 2.0 | 612 |
| diarrhoeaSignal | 1,331 | 2.1 | 2.0 | 758 |
| headache | 1,095 | 1.8 | 1.7 | 364 |
| fatigue | 1,328 | 1.7 | 1.6 | 408 |
| nausea | 1,301 | 1.7 | 1.6 | 346 |
| pain | 908 | 1.5 | 1.4 | 147 |
| off label use | 951 | 1.1 | 1.0 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.